CoChat
Sign Up
Cited by 164

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

APOBEC Enzymes as Targets for Virus and Cancer Therapy

Olson, Margaret E., Harris, Reuben S., Harki, Daniel A.·2018·Cell Chemical Biology
DOI 10.1016/j.chembiol.2017.10.007PMC PMC5775913
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.chembiol.2017.10.007

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 4 references

Research works printed but not linked: 128

  1. Albin, 2010, Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics, Expert Rev. Mol. Med., 12, e4, 10.1017/S1462399409001343 · DOI
  2. Alce, 2004, APOBEC3G is incorporated into virus-like particles by a direct interaction with HIV-1 Gag nucleocapsid protein, J. Biol. Chem., 279, 34083, 10.1074/jbc.C400235200 · DOI
  3. Ali, 2012, Synthesis and structure-activity relationship studies of HIV-1 virion infectivity factor (Vif) inhibitors that block viral replication, ChemMedChem, 7, 1217, 10.1002/cmdc.201200079 · DOI
  4. Baell, 2010, New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays, J. Med. Chem., 53, 2719, 10.1021/jm901137j · DOI
  5. Barnor, 2005, Lentiviral-mediated delivery of combined HIV-1 decoy TAR and Vif siRNA as a single RNA molecule that cleaves to inhibit HIV-1 in transduced cells, Nucleosides Nucleotides Nucleic Acids, 24, 431, 10.1081/NCN-200059981 · DOI
  6. Barnor, 2004, Intracellular expression of antisense RNA transcripts complementary to the human immunodeficiency virus type-1 Vif gene inhibits viral replication in infected T-lymphoblastoid cells, Biochem. Biophys. Res. Commun., 320, 544, 10.1016/j.bbrc.2004.05.201 · DOI
  7. Bennett, 2016, An analog of camptothecin inactive against Topoisomerase I is broadly neutralizing of HIV-1 through inhibition of Vif-dependent APOBEC3G degradation, Antiviral Res., 136, 51, 10.1016/j.antiviral.2016.11.001 · DOI
  8. Betts, 1994, Cytidine deaminase. The 2.3 Å crystal structure of an enzyme: transition-state analog complex, J. Mol. Biol., 235, 635, 10.1006/jmbi.1994.1018 · DOI
  9. Bishop, 2006, Antiviral potency of APOBEC proteins does not correlate with cytidine deamination, J. Virol., 80, 8450, 10.1128/JVI.00839-06 · DOI
  10. Bishop, 2008, APOBEC3G inhibits elongation of HIV-1 reverse transcripts, PLoS Pathog., 4, e1000231, 10.1371/journal.ppat.1000231 · DOI
  11. Bogerd, 2008, Single-stranded RNA facilitates nucleocapsid: APOBEC3G complex formation, RNA, 14, 1228, 10.1261/rna.964708 · DOI
  12. Britan-Rosich, 2011, Multifaceted counter-APOBEC3G mechanisms employed by HIV-1 Vif, J. Mol. Biol., 410, 1065, 10.1016/j.jmb.2011.03.058 · DOI
  13. Browne, 2009, Restriction of HIV-1 by APOBEC3G is cytidine deaminase-dependent, Virology, 387, 313, 10.1016/j.virol.2009.02.026 · DOI
  14. Burnett, 2007, APOBEC3G multimers are recruited to the plasma membrane for packaging into human immunodeficiency virus type 1 virus-like particles in an RNA-dependent process requiring the NC basic linker, J. Virol., 81, 5000, 10.1128/JVI.02237-06 · DOI
  15. Burns, 2013, APOBEC3B is an enzymatic source of mutation in breast cancer, Nature, 494, 366, 10.1038/nature11881 · DOI
  16. Burns, 2013, Evidence for APOBEC3B mutagenesis in multiple human cancers, Nat. Genet., 45, 977, 10.1038/ng.2701 · DOI
  17. Carpenter, 2010, Determinants of sequence-specificity within human AID and APOBEC3G, DNA Repair, 9, 579, 10.1016/j.dnarep.2010.02.010 · DOI
  18. Cen, 2010, Small molecular compounds inhibit HIV-1 replication through specifically stabilizing APOBEC3G, J. Biol. Chem., 285, 16546, 10.1074/jbc.M109.085308 · DOI
  19. Centlivre, 2013, Preclinical in vivo evaluation of the safety of a multi-shRNA-based gene therapy against HIV-1, Mol. Ther. Nucleic Acids, 2, e120, 10.1038/mtna.2013.48 · DOI
  20. Cescon, 2015, APOBEC3B expression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activation, Proc. Natl. Acad. Sci. USA, 112, 2841, 10.1073/pnas.1424869112 · DOI
  21. Chan, 2015, Clusters of multiple mutations: incidence and molecular mechanisms, Annu. Rev. Genet., 49, 243, 10.1146/annurev-genet-112414-054714 · DOI
  22. Cohen, 1971, Cytidine deaminase from Escherichia coli. Purification, properties and inhibition by the potential transition state analog 3,4,5,6-tetrahydrouridine, J. Biol. Chem., 246, 7561, 10.1016/S0021-9258(19)45812-2 · DOI
  23. Conticello, 2008, The AID/APOBEC family of nucleic acid mutators, Genome Biol., 9, 229, 10.1186/gb-2008-9-6-229 · DOI
  24. Conticello, 2003, The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G, Curr. Biol., 13, 2009, 10.1016/j.cub.2003.10.034 · DOI
  25. Conticello, 2005, Evolution of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases, Mol. Biol. Evol., 22, 367, 10.1093/molbev/msi026 · DOI
  26. Di Noia, 2007, Molecular mechanisms of antibody somatic hypermutation, Annu. Rev. Biochem., 76, 1, 10.1146/annurev.biochem.76.061705.090740 · DOI
  27. Ejima, 2011, An anti-HIV-1 compound that increases steady-state expression of apoplipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G, Int. J. Mol. Med., 28, 613
  28. Fan, 2010, Baculiferins A-O, O-sulfated pyrrole alkaloids with anti-HIV-1 activity, from the Chinese marine sponge Iotrochota baculifera, Bioorg. Med. Chem., 18, 5466, 10.1016/j.bmc.2010.06.052 · DOI
  29. Fisher, 1987, The sor gene of HIV-1 is required for efficient virus transmission in vitro, Science, 237, 888, 10.1126/science.3497453 · DOI
  30. Friedman, 1981, The inhibition of DNA(cytosine-5)methylases by 5-azacytidine, Mol. Pharmacol., 19, 314, 10.1016/S0026-895X(25)13486-X · DOI
  31. Gabuzda, 1992, Role of Vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes, J. Virol., 66, 6489, 10.1128/JVI.66.11.6489-6495.1992 · DOI
  32. Haché, 2006, Human APOBEC3 proteins, retrovirus restriction, and HIV drug resistance, AIDS Rev., 8, 148
  33. Harjes, 2013, Impact of H216 on the DNA binding and catalytic activities of the HIV restriction factor APOBEC3G, J. Virol., 87, 7008, 10.1128/JVI.03173-12 · DOI
  34. Harris, 2008, Enhancing immunity to HIV through APOBEC, Nat. Biotechnol., 26, 1089, 10.1038/nbt1008-1089 · DOI
  35. Harris, 2016, Evolutionary paradigms from ancient and ongoing conflicts between the lentiviral Vif protein and mammalian APOBEC3 enzymes, PLoS Pathog., 12, e1005958, 10.1371/journal.ppat.1005958 · DOI
  36. Harris, 2003, DNA determination mediates innate immunity to retroviral infection, Cell, 113, 803, 10.1016/S0092-8674(03)00423-9 · DOI
  37. Harris, 2015, APOBECs and virus restriction, Virology, 479-480, 131, 10.1016/j.virol.2015.03.012 · DOI · Paper page
  38. Harris, 2012, The restriction factors of human immunodeficiency virus, J. Biol. Chem., 287, 40875, 10.1074/jbc.R112.416925 · DOI
  39. Holtz, 2013, APOBEC3G cytosine deamination hotspots are defined by both sequence context and single-stranded DNA secondary structure, Nucleic Acids Res., 41, 6139, 10.1093/nar/gkt246 · DOI
  40. Huang, 2013, Design, synthesis and biological evaluation of indolizine derivatives as HIV-1 VIF-ElonginC interaction inhibitors, Mol. Divers., 17, 221, 10.1007/s11030-013-9424-3 · DOI
  41. Huang, 2013, Indolizine derivatives as HIV-1 VIF-ElonginC interaction inhibitors, Chem. Biol. Drug Des., 81, 730, 10.1111/cbdd.12119 · DOI
  42. Hutchinson, 2016, Genetics: APOBEC conundrum solved, Nat. Rev. Clin. Oncol., 13, 651, 10.1038/nrclinonc.2016.165 · DOI
  43. Imperato, 2015, The RUNX1-PU.1 axis in the control of hematopoiesis, Int. J. Hematol., 101, 319, 10.1007/s12185-015-1762-8 · DOI · Paper page
  44. Ireton, 2003, The 1.14 A crystal structure of yeast cytosine deaminase: evolution of nucleotide salvage enzymes and implications for genetic chemotherapy, Structure, 11, 961, 10.1016/S0969-2126(03)00153-9 · DOI
  45. Iwatani, 2007, Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G, Nucleic Acids Res., 35, 7096, 10.1093/nar/gkm750 · DOI
  46. Iwatani, 2006, Biochemical activities of highly purified, catalytically active human APOBEC3G: correlation with antiviral effect, J. Virol., 80, 5992, 10.1128/JVI.02680-05 · DOI
  47. Janini, 2001, Human immunodeficiency virus type 1 DNA sequences genetically damaged by hypermutation are often abundant in patient peripheral blood mononuclear cells and may be generated during near-simultaneous infection and activation of CD4(+) T cells, J. Virol., 75, 7973, 10.1128/JVI.75.17.7973-7986.2001 · DOI
  48. Jarmuz, 2002, An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22, Genomics, 79, 285, 10.1006/geno.2002.6718 · DOI
  49. Johansson, 2002, Crystal structure of the tetrameric cytidine deaminase from Bacillus subtilis at 2.0 Å resolution, Biochemistry, 41, 2563, 10.1021/bi011849a · DOI
  50. Kan, 1986, Identification of HTLV-III/LAV sor gene product and detection of antibodies in human sera, Science, 231, 1553, 10.1126/science.3006245 · DOI
  51. Khan, 2005, Viral RNA is required for the association of APOBEC3G with human immunodeficiency virus type 1 nucleoprotein complexes, J. Virol., 79, 5870, 10.1128/JVI.79.9.5870-5874.2005 · DOI
  52. Kidd, 2007, Population stratification of a common APOBEC gene deletion polymorphism, PLoS Genet., 3, e63, 10.1371/journal.pgen.0030063 · DOI
  53. Kim, 2014, Human APOBEC3 induced mutation of human immunodeficiency virus type-1 contributes to adaptation and evolution in natural infection, PLoS Pathog., 10, e1004281, 10.1371/journal.ppat.1004281 · DOI
  54. Kim, 2010, Human APOBEC3G-mediated editing can promote HIV-1 sequence diversification and accelerate adaptation to selective pressure, J. Virol., 84, 10402, 10.1128/JVI.01223-10 · DOI
  55. Kitamura, 2012, The APOBEC3C crystal structure and the interface for HIV-1 Vif binding, Nat. Struct. Mol. Biol., 19, 1005, 10.1038/nsmb.2378 · DOI
  56. Knisbacher, 2016, DNA editing by APOBECs: a genomic preserver and transformer, Trends Genet., 32, 16, 10.1016/j.tig.2015.10.005 · DOI
  57. Ko, 2003, Crystal structure of yeast cytosine deaminase. Insights into enzyme mechanism and evolution, J. Biol. Chem., 278, 19111, 10.1074/jbc.M300874200 · DOI
  58. Kohli, 2010, Local sequence targeting in the AID/APOBEC family differentially impacts retroviral restriction and antibody diversification, J. Biol. Chem., 285, 40956, 10.1074/jbc.M110.177402 · DOI
  59. Kouno, 2017, Crystal structure of APOBEC3A bound to single-stranded DNA reveals structural basis for cytidine deamination and specificity, Nat. Commun., 8, 15024, 10.1038/ncomms15024 · DOI
  60. LaRue, 2009, Guidelines for naming nonprimate APOBEC3 genes and proteins, J. Virol., 83, 494, 10.1128/JVI.01976-08 · DOI
  61. Law, 2016, The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer, Sci. Adv., 2, e1601737, 10.1126/sciadv.1601737 · DOI
  62. Lecossier, 2003, Hypermutation of HIV-1 DNA in the absence of the Vif protein, Science, 300, 1112, 10.1126/science.1083338 · DOI
  63. Lee, 1986, A new HTLV-III/LAV protein encoded by a gene found in cytopathic retroviruses, Science, 231, 1546, 10.1126/science.3006243 · DOI
  64. Letko, 2015, Identification of the HIV-1 Vif and human APOBEC3G protein interface, Cell Rep., 13, 1789, 10.1016/j.celrep.2015.10.068 · DOI
  65. Li, 2012, First-in-class small molecule inhibitors of the single-strand DNA cytosine deaminase APOBEC3G, ACS Chem. Biol., 7, 506, 10.1021/cb200440y · DOI
  66. Lin, 2011, Integration of BMP, Wnt, and Notch signaling pathways in osteoblast differentiation, J. Cell Biochem., 112, 3491, 10.1002/jcb.23287 · DOI
  67. Luo, 2004, Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging, J. Virol., 78, 11841, 10.1128/JVI.78.21.11841-11852.2004 · DOI
  68. Lv, 2007, Three-dimensional structure of HIV-1 VIF constructed by comparative modeling and the function characterization analyzed by molecular dynamics simulation, Org. Biomol. Chem., 5, 617, 10.1039/b612050d · DOI
  69. Malim, 2012, HIV restriction factors and mechanisms of evasion, Cold Spring Harb. Perspect. Med., 2, a006940, 10.1101/cshperspect.a006940 · DOI
  70. Malim, 2008, HIV-1 accessory proteins—ensuring viral survival in a hostile environment, Cell Host Microbe, 3, 388, 10.1016/j.chom.2008.04.008 · DOI
  71. Marin, 2003, HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation, Nat. Med., 9, 1398, 10.1038/nm946 · DOI
  72. Marquez, 2005, Zebularine: a unique molecule for an epigenetically based strategy in cancer chemotherapy. The magic of its chemistry and biology, Nucleosides Nucleotides Nucleic Acids, 24, 305, 10.1081/NCN-200059765 · DOI
  73. Matsui, 2014, Small molecules that inhibit Vif-induced degradation of APOBEC3G, Virol. J., 11, 122, 10.1186/1743-422X-11-122 · DOI
  74. Mbisa, 2007, Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration, J. Virol., 81, 7099, 10.1128/JVI.00272-07 · DOI
  75. Mehle, 2004, Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway, J. Biol. Chem., 279, 7792, 10.1074/jbc.M313093200 · DOI
  76. Mertz, 2017, Risks at the DNA replication fork: effects upon carcinogenesis and tumor heterogeneity, Genes, 8, 46, 10.3390/genes8010046 · DOI
  77. Miyagi, 2007, Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1, J. Virol., 81, 13346, 10.1128/JVI.01361-07 · DOI
  78. Mohammed, 2012, SAR and lead optimization of an HIV-1 Vif-APOBEC3G axis inhibitor, ACS Med. Chem. Lett., 3, 465, 10.1021/ml300037k · DOI
  79. Mulder, 2008, Cytidine deamination induced HIV-1 drug resistance, Proc. Natl. Acad. Sci. USA, 105, 5501, 10.1073/pnas.0710190105 · DOI
  80. Nabel, 2013, Nucleic acid determinants for selective deamination of DNA over RNA by activation-induced deaminase, Proc. Natl. Acad. Sci. USA, 110, 14225, 10.1073/pnas.1306345110 · DOI
  81. Nakashima, 2015, Structural insights into HIV-1 Vif-APOBEC3F interaction, J. Virol., 90, 1034, 10.1128/JVI.02369-15 · DOI
  82. Nakaya, 2016, In vivo examination of mouse APOBEC3- and human APOBEC3A- and APOBEC3G-mediated restriction of parvovirus and herpesvirus infection in mouse models, J. Virol., 90, 8005, 10.1128/JVI.00973-16 · DOI
  83. Nathans, 2008, Small-molecule inhibition of HIV-1 Vif, Nat. Biotechnol., 26, 1187, 10.1038/nbt.1496 · DOI
  84. Newman, 2005, Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity, Curr. Biol., 15, 166, 10.1016/j.cub.2004.12.068 · DOI
  85. Nik-Zainal, 2012, Mutational processes molding the genomes of 21 breast cancers, Cell, 149, 979, 10.1016/j.cell.2012.04.024 · DOI · Paper page
  86. Olson, 2015, Oxidative reactivities of 2-furylquinolines: ubiquitous scaffolds in common high-throughput screening libraries, J. Med. Chem., 58, 7419, 10.1021/acs.jmedchem.5b00930 · DOI
  87. Olson, 2013, Small-molecule APOBEC3G DNA cytosine deaminase inhibitors based on a 4-amino-1,2,4-triazole-3-thiol scaffold, ChemMedChem, 8, 112, 10.1002/cmdc.201200411 · DOI
  88. Pan, 2015, Development of benzimidazole derivatives to inhibit HIV-1 replication through protecting APOBEC3G protein, Eur. J. Med. Chem., 95, 500, 10.1016/j.ejmech.2015.03.050 · DOI
  89. Pery, 2015, Redoxal, an inhibitor of de novo pyrimidine biosynthesis, augments APOBEC3G antiviral activity against human immunodeficiency virus type 1, Virology, 484, 276, 10.1016/j.virol.2015.06.014 · DOI
  90. Pery, 2015, Identification of a novel HIV-1 inhibitor targeting Vif-dependent degradation of human APOBEC3G protein, J. Biol. Chem., 290, 10504, 10.1074/jbc.M114.626903 · DOI
  91. Petersen-Mahrt, 2003, In vitro deamination of cytosine to uracil in single-stranded DNA by apolipoprotein B editing complex catalytic subunit 1 (APOBEC1), J. Biol. Chem., 278, 19583, 10.1074/jbc.C300114200 · DOI
  92. Rathore, 2013, The local dinucleotide preference of APOBEC3G can be altered from 5′-CC to 5′-TC by a single amino acid substitution, J. Mol. Biol., 425, 4442, 10.1016/j.jmb.2013.07.040 · DOI
  93. Rausch, 2009, Dissecting APOBEC3G substrate specificity by nucleoside analog interference, J. Biol. Chem., 284, 7047, 10.1074/jbc.M807258200 · DOI
  94. Refsland, 2013, The APOBEC3 family of retroelement restriction factors, Curr. Top. Microbiol. Immunol., 371, 1
  95. Refsland, 2014, Natural polymorphisms in human APOBEC3H and HIV-1 Vif combine in primary T lymphocytes to affect viral G-to-a mutation levels and infectivity, PLoS Genet., 10, e1004761, 10.1371/journal.pgen.1004761 · DOI
  96. Richards, 2015, The binding interface between human APOBEC3F and HIV-1 Vif elucidated by genetic and computational approaches, Cell Rep., 13, 1781, 10.1016/j.celrep.2015.10.067 · DOI
  97. Richards, 2017, Reassessing APOBEC3G inhibition by HIV-1 Vif-derived peptides, J. Mol. Biol., 429, 88, 10.1016/j.jmb.2016.11.012 · DOI
  98. Robbiani, 2013, Chromosome translocation, B cell lymphoma, and activation-induced cytidine deaminase, Annu. Rev. Pathol., 8, 79, 10.1146/annurev-pathol-020712-164004 · DOI
  99. Roberts, 2013, An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers, Nat. Genet., 45, 970, 10.1038/ng.2702 · DOI
  100. Salter, 2016, The APOBEC protein family: united by structure, divergent in function, Trends Biochem. Sci., 41, 578, 10.1016/j.tibs.2016.05.001 · DOI · Paper page
  101. Schafer, 2004, Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor, Virology, 328, 163, 10.1016/j.virol.2004.08.006 · DOI
  102. Schumacher, 2008, The DNA deaminase activity of human APOBEC3G is required for Ty1, MusD, and human immunodeficiency virus type 1 restriction, J. Virol., 82, 2652, 10.1128/JVI.02391-07 · DOI
  103. Shaban, N.M., Shi, K., Lauer, K.V., Carpenter, M.A., Richards, C.M., Lopresti, M.W., Salamango, D., Wang, J., Banerjee, S., Brown, W.L., et al. (2017). bioRxiv 203000; https://doi.org/10.1101/203000. · DOI
  104. Shaban, 2016, 1.92 angstrom zinc-free APOBEC3F catalytic domain crystal structure, J. Mol. Biol., 428, 2307, 10.1016/j.jmb.2016.04.026 · DOI
  105. Sheehy, 2003, The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif, Nat. Med., 9, 1404, 10.1038/nm945 · DOI
  106. Shi, 2017, Structural basis for targeted DNA cytosine deamination and mutagenesis by APOBEC3A and APOBEC3B, Nat. Struct. Mol. Biol., 24, 131, 10.1038/nsmb.3344 · DOI
  107. Shi, 2015, Crystal structure of the DNA deaminase APOBEC3B catalytic domain, J. Biol. Chem., 290, 28120, 10.1074/jbc.M115.679951 · DOI
  108. Sieuwerts, 2014, Elevated APOBEC3B correlates with poor outcomes for estrogen-receptor-positive breast cancers, Horm. Cancer, 5, 405, 10.1007/s12672-014-0196-8 · DOI
  109. Sinha, 2015, An in silico approach for identification of novel inhibitors as a potential therapeutics targeting HIV-1 viral infectivity factor, Curr. Top. Med. Chem., 15, 65, 10.2174/1568026615666150112114337 · DOI
  110. Smith, 2009, Multiple ways of targeting APOBEC3-virion infectivity factor interactions for anti-HIV-1 drug development, Trends Pharmacol. Sci., 30, 638, 10.1016/j.tips.2009.09.006 · DOI
  111. Sodroski, 1986, Replicative and cytopathic potential of HTLV-III/LAV with sor gene deletions, Science, 231, 1549, 10.1126/science.3006244 · DOI
  112. Spanevello, 2016, Development of lentiviral vectors simultaneously expressing multiple siRNAs against CCR5, Vif and tat/rev genes for an HIV-1 gene therapy approach, Mol. Ther. Nucleic Acids, 19, 24
  113. Strebel, 1987, The HIV 'A' (sor) gene product is essential for virus infectivity, Nature, 328, 728, 10.1038/328728a0 · DOI
  114. Svarovskaia, 2004, Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs, J. Biol. Chem., 279, 35822, 10.1074/jbc.M405761200 · DOI
  115. von Schwedler, 1993, Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells, J. Virol., 67, 4945, 10.1128/JVI.67.8.4945-4955.1993 · DOI
  116. Wang, 2010, Altering the spectrum of immunoglobulin V gene somatic hypermutation by modifying the active site of AID, J. Exp. Med., 207, 141, 10.1084/jem.20092238 · DOI
  117. Wedekind, 2003, Messenger RNA editing in mammals: new members of the APOBEC family seeking roles in the family business, Trends Genet., 19, 207, 10.1016/S0168-9525(03)00054-4 · DOI
  118. Weil, 2013, Uracil DNA glycosylase initiates degradation of HIV-1 cDNA containing misincorporated dUTP and prevents viral integration, Proc. Natl. Acad. Sci. USA, 110, E448, 10.1073/pnas.1219702110 · DOI
  119. Wolfenden, 1991, Testing the limits of protein-ligand binding discrimination with transition-state analogue inhibitors, Acc. Chem. Res., 24, 209, 10.1021/ar00007a004 · DOI
  120. Xie, 2004, The structure of a yeast RNA-editing deaminase provides insight into the fold and function of activation-induced deaminase and APOBEC-1, Proc. Natl. Acad. Sci. USA, 101, 8114, 10.1073/pnas.0400493101 · DOI
  121. Yang, 2007, Virion-associated uracil DNA glycosylase-2 and apurinic/apyrimidinic endonuclease are involved in the degradation of APOBEC3G-edited nascent HIV-1 DNA, J. Biol. Chem., 282, 11667, 10.1074/jbc.M606864200 · DOI
  122. Yu, 2004, Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome, Nat. Struct. Mol. Biol., 11, 435, 10.1038/nsmb758 · DOI
  123. Yu, 2003, Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex, Science, 302, 1056, 10.1126/science.1089591 · DOI
  124. Zhang, 2003, The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA, Nature, 424, 94, 10.1038/nature01707 · DOI
  125. Zhang, 2011, T-cell differentiation factor CBF-beta regulates HIV-1 Vif-mediated evasion of host restriction, Nature, 481, 376, 10.1038/nature10718 · DOI
  126. Zhou, 2013, Exploring the binding mode of HIV-1 Vif inhibitors by blind docking, molecular dynamics and MM/GBSA, RSC Adv., 3, 22532, 10.1039/c3ra42291g · DOI
  127. Zhou, 2017, Synthesis, biological evaluation and molecular docking study of N-(2-methoxyphenyl)-6-((4-nitrophenyl)sulfonyl)benzamide derivatives as potent HIV-1 Vif antagonists, Eur. J. Med. Chem., 129, 310, 10.1016/j.ejmech.2017.01.010 · DOI
  128. Zuo, 2012, Small-molecule inhibition of human immunodeficiency virus type 1 replication by targeting the interaction between Vif and ElonginC, J. Virol., 86, 5497, 10.1128/JVI.06957-11 · DOI

Cited by

Sorted by citations

Metadata

Authors
Olson, M. E., Harris, R. S., & Harki, D. A.
Venue
Cell Chemical Biology
Publisher
Elsevier BV
Published
2018-01
Volume
25
Issue
1
Pages
36-49
ISSN
2451-9456
DOI
10.1016/j.chembiol.2017.10.007
PMC
PMC5775913
Cited by
164
References
4
Language
en
Licence
Funders
NIH (R01-GM110129, R01-GM118000, R37-AI064046, R21-CA206309, F31-CA183246)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review